Open AccessIntermittent Antibody-Based Combination Therapy Removes Alloantibodies and Achieves Indefinite Heart Transplant Survival in Presensitized Recipients
Author(s) -
Hina Shariff,
Yakup Tanriver,
Kathryn Brown,
Lucy Meader,
Roseanna Greenlaw,
Nizam Mamode,
Stipo Jurčević
Publication year - 2010
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/tp.0b013e3181e228bd
Subject(s) - medicine , elispot , cd8 , heart transplantation , combination therapy , immunology , transplantation , t cell , cd154 , splenocyte , cell therapy , antibody , immune system , cytotoxic t cell , cell , cd40 , biology , biochemistry , in vitro , genetics
It is well established that primed/memory T cells play a critical role in heart transplant rejection. This contributes to the challenges faced in the transplant clinic because current treatments that are efficient in controlling naïve T cell alloresponses have limited efficacy on primed T cell responders.